keyword
MENU ▼
Read by QxMD icon Read
search

radioiodine

keyword
https://www.readbyqxmd.com/read/29786126/prophylactic-central-compartment-neck-dissection-in-papillary-thyroid-cancer-and-effect-on-locoregional-recurrence
#1
David T Hughes, Jennifer E Rosen, Douglas B Evans, Elizabeth Grubbs, Tracy S Wang, Carmen C Solórzano
BACKGROUND: Prophylactic central compartment neck dissection (pCCND) in addition to total thyroidectomy (TT) includes removal of central compartment lymph nodes in the absence of clinical involvement on preoperative and intraoperative evaluation. The data regarding the influence of pCCND on oncologic outcomes and surgical complication rates is mixed and, therefore, is the focus of this analysis. METHODS: A systematic review of the literature on total thyroidectomy with prophylactic central compartment neck dissection (TT + pCCND) from January 1990 to October 2017 identified 221 abstracts of which 17 met inclusion criteria and were reviewed (1 randomized-control trial, 13 retrospective cohort studies, and 3 meta-analyses)...
May 21, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29783774/d-amino-acid-peptide-residualizing-agents-for-protein-radioiodination-effect-of-aspartate-for-glutamate-substitution
#2
Marek Pruszynski, Choong Mo Kang, Eftychia Koumarianou, Ganesan Vaidyanathan, Michael R Zalutsky
The residualizing prosthetic agent N ε -(3-[* I]iodobenzoyl)-Lys⁵- N α -maleimido-Gly¹-d-GEEEK ([* I]IB-Mal-d-GEEEK) showed promise for the radioiodination of monoclonal antibodies (mAbs) that bind to internalizing molecular targets. Although enhanced tumor uptake was achieved in these studies, elevated kidney accumulation also was observed, particularly with low-molecular-weight, single-domain antibody fragments (sdAbs). Here, we developed an analogous agent (IB-Mal-d-GDDDK), in which glutamate residues (E) were replaced with aspartates (D) to determine whether this modification could decrease renal uptake...
May 20, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29780557/pd-nanosheets-with-their-surface-coordinated-by-radioactive-iodide-as-a-high-performance-theranostic-nanoagent-for-orthotopic-hepatocellular-carcinoma-imaging-and-cancer-therapy
#3
Mei Chen, Zhide Guo, Qinghua Chen, Jingping Wei, Jingchao Li, Changrong Shi, Duo Xu, Dawang Zhou, Xianzhong Zhang, Nanfeng Zheng
Radiolabeled nanoparticles (NPs), taking advantage of nanotechnology and nuclear medicine, have shown attractive potential for cancer diagnosis and therapy. However, the high background signal in the liver and long-term toxic effects of radioisotopes caused by the nonselective accumulation of radiolabeled nanoparticles in organs have become the major challenges. Here, we report a pH-sensitive multifunctional theranostic platform with radiolabeled Pd nanosheets through a simple mixture of ultra-small Pd nanosheets and radioisotopes utilizing the strong adsorption of 131 I and 125 I on their surfaces (denoted as 131 I-Pd-PEG or 125 I-Pd-PEG)...
May 14, 2018: Chemical Science
https://www.readbyqxmd.com/read/29762469/individualised-multimodal-treatment-strategies-for-anaplastic-and-poorly-differentiated-thyroid-cancer
#4
Sabine Wächter, Annette Wunderlich, Silvia Roth, Ioannis Mintziras, Elisabeth Maurer, Sebastian Hoffmann, Frederik A Verburg, Sebastian A Fellinger, Katharina Holzer, Detlef K Bartsch, Pietro Di Fazio
The prognosis of anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC) is poor, due to their radioiodine refractoriness (RAI-R), high metastatic potential and current lack of effective treatment strategies. We aimed to examine the efficacy of the tyrosine kinase inhibitors (TKIs) sorafenib and selumetinib and the histone deacetylase inhibitor (HDACI) panobinostat in patient-derived tumor tissue (PDTT) of ATCs/PDTCs, the expression of sodium iodide symporter ( NIS ) and radioiodine up-take (RAI-U)...
May 15, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29762261/a-retrospective-study-of-the-clinical-features-in-papillary-thyroid-microcarcinoma-depending-on-age
#5
Xuan Wang, Jian Tan, Wei Zheng, Ning Li
The aim of this study was to evaluate the clinical features and correlation of neck lymph node involvement of papillary thyroid microcarcinoma (PTMC) according to patients' age. We divided the patients into three groups according to age: young group (<45 years, n=83), middle group (45-54 years, n=80), and old group (≥55 years, n=53). The clinical features among the different groups were analyzed retrospectively. All of the 216 patients had received radioiodine ablation at least one time. Among these, 84 patients had central lymph node metastasis (CLNM), 11 patients had lateral lymph node metastasis (LLNM), and 26 patients had both CLNM and LLNM...
May 14, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29762246/brafv600e-mutation-does-not-significantly-affect-the-efficacy-of-radioiodine-therapy-in-patients-with-papillary-thyroid-carcinoma-without-known-distant-metastases
#6
Guohua Shen, Ying Kou, Bin Liu, Rui Huang, Anren Kuang
PURPOSE: The BRAF mutation is the most common and specific oncogenic event in papillary thyroid carcinoma (PTC). However, its role in radioiodine therapy decision making has yet to be established. This study aimed to evaluate the impact of the BRAF mutation on the clinical response to radioiodine therapy. METHODS: This retrospective study included PTC patients who received total thyroidectomy with lymph node dissection, radioiodine therapy, and thyroid-stimulating hormone suppression between January 2012 and March 2016...
May 14, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29761277/treatment-of-differentiated-thyroid-cancer-can-endoscopic-thyroidectomy-via-a-chest-breast-approach-achieve-similar-therapeutic-effects-as-open-surgery
#7
Rui Qu, Jinyi Li, Jingge Yang, Peng Sun, Jian Gong, Cunchuan Wang
BACKGROUND: An analysis of some special factors was performed to further evaluate and discuss whether endoscopic surgery and traditional open surgery have similar therapeutic outcomes for differentiated thyroid cancer (DTC). METHODS: A retrospective study was performed on 76 patients undergoing surgery to treat DTC. Forty patients were treated by endoscopic thyroidectomy via the chest-breast approach (endoscopic group) and thirty-six patients were treated by open surgery (open group)...
May 14, 2018: Surgical Endoscopy
https://www.readbyqxmd.com/read/29756327/use-of-radioiodine-131-scan-to-measure-influence-of-surgical-discipline-practice-and-volume-on-residual-thyroid-tissue-after-total-thyroidectomy-for-differentiated-thyroid-carcinoma
#8
Jin Soo A Song, Nico Moolman, Steven Burrell, Murali Rajaraman, Martin Joseph Bullock, Jonathan Trites, S Mark Taylor, Matthew H Rigby, Robert D Hart
BACKGROUND: Our study's purpose is to determine the influence of surgical discipline, surgeon site, and volume on remnant thyroid tissue visualized on radioactive iodine-131 (I-131) scans after total thyroidectomy and I-131 ablation in patients with well-differentiated thyroid carcinomas. METHODS: We retrospectively reviewed all cases of patients who received I-131 therapeutic ablation and postablation radioactive I-131 scans at our center after thyroidectomy to calculate the fraction of administered dose multiplied by 1000 (UDR1000)...
May 13, 2018: Head & Neck
https://www.readbyqxmd.com/read/29755799/spontaneous-regression-of-metastatic-papillary-thyroid-cancer-in-a-lymph-node
#9
Jien Shim, Jianyu Rao, Run Yu
Spontaneous regression of cancer is defined as disappearance of cancer in the absence of specific therapy. In thyroid cancer patients with biochemically incomplete response to initial treatments, spontaneous decline in thyroglobulin levels without any cancer treatment is a well-known phenomenon; however, spontaneous regression of persistent or recurrent structural disease has not been reported. We here present a case of papillary thyroid cancer in a 58-year-old female who underwent total thyroidectomy and two radioiodine ablations...
2018: Case Reports in Endocrinology
https://www.readbyqxmd.com/read/29754217/investigation-of-factors-influencing-radioiodine-131-i-biokinetics-in-patients-with-benign-thyroid-disease-using-nonlinear-mixed-effects-approach
#10
Valentina Topić Vučenović, Zvezdana Rajkovača, Dijana Jelić, Dragi Stanimirović, Goran Vuleta, Branislava Miljković, Katarina Vučićević
PURPOSE: Radioiodine (131 I) therapy is the common treatment option for benign thyroid diseases. The objective of this study was to characterize 131 I biokinetics in patients with benign thyroid disease and to investigate and quantify the influence of patients' demographic and clinical characteristics on intra-thyroidal 131 I kinetics by developing a population model. METHODS: Population pharmacokinetic analysis was performed using a nonlinear mixed effects approach...
May 13, 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29753522/silver-functionalized-silica-aerogels-and-their-application-in-the-removal-of-iodine-from-aqueous-environments
#11
R Matthew Asmussen, Josef Matyáš, Nikolla P Qafoku, Albert A Kruger
One of the key challenges for radioactive waste management is the efficient capture and immobilization of radioiodine, because of its radiotoxicity, high mobility in the environment, and long half-life (t1/2  = 1.57 × 107 years). Silver-functionalized silica aerogel (AgAero) represents a strong candidate for safe sequestration of radioiodine from various nuclear waste streams and subsurface environments. Batch sorption experiments up to 10 days long were carried out in oxic and anoxic conditions in both deionized water (DIW) and various Hanford Site Waste Treatment Plant (WTP) off-gas condensate simulants containing from 5 to 10 ppm of iodide (I- ) or iodate (IO3 - )...
May 1, 2018: Journal of Hazardous Materials
https://www.readbyqxmd.com/read/29752332/prolonged-duration-of-response-in-lenvatinib-responders-with-thyroid-cancer
#12
Andrew G Gianoukakis, Corina E Dutcus, Nicolas Batty, Matthew Guo, Mahadi Baig
We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary analysis. In this randomized, double-blind, multicenter, placebo-controlled phase 3 study, patients ≥18 years old with measurable, pathologically confirmed RR-DTC with independent radiologic confirmation of disease progression within the previous 13 months were randomized 2:1 to oral lenvatinib 24 mg/day or placebo. The main outcome measures for this analysis are DOR and progression-free survival (PFS)...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29749906/correction-to-tertiary-care-experience-of-sorafenib-in-the-treatment-of-progressive-radioiodine-refractory-differentiated-thyroid-carcinoma-a-korean-multicenter-study-by-kim-m-kim-th-shin-dy-lim-dj-kim-ey-kim-wb-chung-jh-shong-yk-kim-bh-and-kim-wg-on-behalf
#13
https://www.readbyqxmd.com/read/29748234/radioiodine-therapy-in-differentiated-thyroid-cancer-a-matter-of-controversy-pro-radioiodine
#14
Matthias Schmidt, Rainer Görges, Alexander Drzezga, Markus Dietlein
Radioiodine therapy is a matter of controversy as different opinions exist towards its use in patients with differentiated thyroid carcinoma. The following article sheds light on different opinions and explains why the authors advocate the use of radioiodine therapy not only in high-risk patients. In comparison to other malignancies differentiated thyroid carcinoma has a different tumor biology due to its usually slow growth pattern. Radioiodine therapy was first used about 75 years ago and provided cure at a time when prospective randomized controlled trials were to be developed...
May 10, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29741290/comparison-of-high-intensity-focused-ultrasound-and-radioiodine-for-treating-toxic-thyroid-nodules
#15
Luca Giovanella, Arnoldo Piccardo, Cinzia Pezzoli, Fabiano Bini, Riccardo Ricci, Teresa Ruberto, Pierpaolo Trimboli
PURPOSE: We compared the effectiveness of high intensity focused ultrasound (HIFU) and radioiodine (RAI) to treat patients carrying toxic thyroid nodule (TTN). Normalization of serum thyrotropin (TSH) 1 year after treatment was the primary endpoint; concurrent changes in nodules' volume and scintigraphic pattern were also evaluated as secondary endpoints. MATERIALS AND METHODS: Among patients ≥18 years old with TTN observed at our centre between January 1st , 2016 and December 31th , 2016 we prospectively enrolled 17 and 15 age and sex-matched patients treated with RAI and HIFU, respectively...
May 9, 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29740497/clinical-outcomes-and-associated-factors-of-radioiodine-131-treatment-in-differentiated-thyroid-cancer-with-cervical-lymph-node-metastasis
#16
Chung-Jie Cao, Cheng-Yun Dou, Jiayan Lian, Zhao-Sheng Luan, Wen Zhou, Wenlin Xie, Li Chen, Kehua Zhou, Hong Lai
Cervical lymph node metastasis (CLNM) is common in differentiated thyroid cancer (DTC). Radioiodine-131 (131 I) treatment is recommended for the removal of residual thyroid tissue following thyroidectomy. To date, the effect of 131 I therapy on the outcomes of patients with DTC with CLNM is unclear. The aim of the present study was to evaluate the final outcome of patients with DTC with CLNM according to 131 I administration, and to analyze the factors that may affect clinical outcomes. A total of 357 patients with DTC with CLNM were recruited and divided into three groups: Those who received 2, 3 or 4 doses of 131 I therapy, respectively...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29733973/design-and-development-of-microemulsion-systems-of-a-new-antineoplaston-a10-analog-for-enhanced-intravenous-antitumor-activity-in-vitro-characterization-molecular-docking-125-i-radiolabeling-and-in-vivo-biodistribution-studies
#17
Mohamed H Aboumanei, Aly A Abdelbary, Ismail T Ibrahim, Mina I Tadros, Mohamed T El-Kolaly
A10, (3-phenylacetylamino-2,6-piperidinedione), is a natural peptide with broad antineoplastic activity. Recently, in vitro antitumor effect of a new A10 analog [3-(4-methoxybenzoylamino)-2,6-piperidinedione] (MPD) has been verified. However, poor aqueous solubility represents an obstacle towards intravenous formulation of MPD and impedes successful in vivo antitumor activity. To surmount such limitation, MPD microemulsion (MPDME) was developed. A 31 22 full factorial design using Design-Expert® software was adopted to study the influence of different parameters and select the optimum formulation (MPDME1)...
May 4, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29729004/italian-consensus-on-diagnosis-and-treatment-of-differentiated-thyroid-cancer-joint-statements-of-six-italian-societies
#18
F Pacini, F Basolo, R Bellantone, G Boni, M A Cannizzaro, M De Palma, C Durante, R Elisei, G Fadda, A Frasoldati, L Fugazzola, R Guglielmi, C P Lombardi, P Miccoli, E Papini, G Pellegriti, L Pezzullo, A Pontecorvi, M Salvatori, E Seregni, P Vitti
BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. METHODS: Six scientific Italian societies entitled to cure thyroid cancer patients (the Italian Thyroid Association, the Medical Endocrinology Association, the Italian Society of Endocrinology, the Italian Association of Nuclear Medicine and Molecular Imaging, the Italian Society of Unified Endocrine Surgery and the Italian Society of Anatomic Pathology and Diagnostic Cytology) felt the need to develop a consensus report based on significant scientific advances occurred in the field...
May 4, 2018: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/29723098/concerns-about-the-risk-of-myeloid-malignancies-after-radioiodine-therapy-in-thyroid-cancer
#19
Martina Sollini, Arturo Chiti
No abstract text is available yet for this article.
May 3, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29723095/questionable-relevance-of-leukemia-risk-after-radioiodine-ablation-of-thyroid-cancer
#20
Ronald Fisher
No abstract text is available yet for this article.
May 3, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
100757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"